Reddy’s Looks To Be Its Own Boss As It Gears Up For GLP-1 Opportunities
Main Strength In APIs, Firm Believes, Which ‘Allow Us To Scale Up Very, Very Nicely’
Dr Reddy’s Laboratories has spoken at length about its ability to make most of its GLP-1 APIs and formulations in-house, as it looks to be a ‘day one’ player for opportunities including semaglutide.
